Puma Q2 NERLYNX revenue $44.4M (-14% YoY); GAAP net loss $4.5M vs profit $2.1M

PUMA BIOTECHNOLOGY, INC.

2024-Q2 EPS reported -$0.19 revenue$90,849,000

Q2 2024 product revenue $44.4M (down from $51.6M in Q2 2023); total revenue $47.1M incl $2.7M royalties.
GAAP net loss $4.5M ($0.09 loss per share) vs net income $2.1M ($0.05 EPS) in Q2 2023.
Non-GAAP adjusted net loss $2.5M ($0.05 loss per share) vs adjusted net income $4.6M ($0.10 EPS).
Cash & equivalents $96.8M at June 30, 2024; net cash from ops $1.0M in Q2.
FY2024 guidance: net product revenue $183-190M, net income $12-15M; Q3 net product revenue $50-53M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.